Prostate Cancer Diagnostics Market Outlook:
Prostate Cancer Diagnostics Market size was valued at USD 9.05 billion in 2025 and is set to exceed USD 16.99 billion by 2035, registering over 6.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of prostate cancer diagnostics is evaluated at USD 9.58 billion.
The prostate cancer diagnostics market is expected to witness steady growth due to the increasing demand for advanced diagnostic tools, stimulated by increased incidence rates of prostate cancer and an expanding geriatric population. Given the importance of early detection, healthcare providers continue to invest in new technologies while making diagnostic services more widely accessible. For example, Cortechs.ai launched OnQ Prostate in May 2024 which is a software that's been cleared by the FDA to detect prostate cancer. Such advancements, along with a strong emphasis on precision diagnosis, coupled with government-funded initiatives that advance screening capabilities and create public awareness regarding health, boost market growth.
The prostate cancer diagnostics industry is being actively supported by governments worldwide through funds and awareness-raising, especially for early detection and preventive care. Many governmental health departments report their increased investments in cancer screening programs across less privileged regions. In 2024, the U.S. government declared funding of USD 9 million to be invested in August to increase access to cancer screening across health centers in various regions. This governmental support is instrumental in widening the scope of diagnostics of prostate cancer by providing wider access to advanced tools and increasing the rate of early detection, thus improving patients' outcomes.
